...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>AIDS Research and Human Retroviruses >Factors Associated with Daily Tenofovir Exposure in Thai Subjects Taking Combination Antiretroviral Therapy
【24h】

Factors Associated with Daily Tenofovir Exposure in Thai Subjects Taking Combination Antiretroviral Therapy

机译：泰国受试者每日崇高罗维尔暴露的因素采用组合抗逆转录病毒治疗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Tenofovir (TFV) exposure is associated with antiretroviral efficacy and risk of kidney disease. There is evidence of high interindividual variability of the pharmacokinetics of TFV. The effect of several clinical conditions on the pharmacokinetics of TFV has been observed and may partly explain its variability. We assessed factors influencing the pharmacokinetics of TFV in Thai patients. Thirty participants (50% female) taking efavirenz- or ritonavir-boosted protease inhibitor-based regimens were investigated. Intensive pharmacokinetic sampling was performed over 24 h. Multivariate geometric mean regression models adjusted for covariates with p <= 0.2 in univariate analysis were developed. The median age was 41 years. Five participants [three taking a protease inhibitor (PI) and two taking efavirenz (EFV)] had mild renal dysfunction [estimated glomerular filtration rate (eGFR) 60-90 ml/min/1.73 m(2); range 72-89]. TFV AUC(0-24) was 23% (95% CI 1-49%; p=0.04) higher in those taking PI vs. EFV, 39% (95% CI 5-84%; p=0.02) higher in those with mild renal dysfunction, and reduced by 16% (95% CI 5-26%; p=0.008) with each 10 kg body weight increase, after adjusting for sex and duration of TFV exposure. In PI-treated subjects TFV AUC(0-24) increased by 3% (0.3-6%; p=0.03) for each mg center dot h/liter increase in ritonavir (RTV) AUC(0-24) after adjusting for sex, weight, mild renal impairment, and proximal renal tubular dysfunction. Significantly higher TFV exposures were independently associated with PI regimens, mild renal impairment, lower body weight, and increasing RTV AUC(0-24). Clinicians should be aware of the effect of these factors on TFV exposure when this drug is prescribed.
机译：替诺福韦（TFV）暴露与抗逆转录病毒疗效和肾病的风险有关。有证据表明TFV的药代动力学的高接合变异性。已经观察到几种临床条件对TFV的药代动力学的影响，并可能部分解释其可变性。我们评估了影响泰国患者TFV药代动力学的因素。研究了服用eFaviravir-或ritonavir-促进蛋白酶抑制剂的方案的三十名参与者（50％的女性）。强化药代动力学取样量超过24小时进行。开发了对单变量分析中的P <= 0.2调节的多变量几何平均回归模型。中位年龄为41岁。五个参与者[三次服用蛋白酶抑制剂（PI）和两次服用Efavirenz（EFV）]具有轻度肾功能紊乱[估计肾小球过滤速率（EGFR）60-90ml / min / 1.73m（2）;范围72-89]。 TFV AUC（0-24）为PI与EFV的PI与EFV，39％（95％CI 5-84％; P = 0.02）在那些中较高23％（95％CI 1-49％; P = 0.04）肾功能紊乱，减少16％（95％CI 5-26％; P = 0.008），每10千克体重增加，调整性别和TFV暴露的持续时间后。在治疗性别后，在PI治疗的受试者中，TFV AUC（0-24）增加了每麦克昔（RTV）AUC（0-24）的每麦克韦（RTV）AUC（0-24）中的每次Mg中心点H /升增加3％（0.3-6％; p = 0.03） ，体重，肾损伤和近端肾小管功能障碍。显着较高的TFV曝光与PI方案，轻度肾损伤，下体重和增加RTV AUC（0-24）独立相关。临床医生应了解这些因素在规定该药物时对TFV暴露的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号